• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Japan·Healthcare·2796.T
Share

Pharmarise Holdings Corporation Stocks

¥ 509Last Updated 20.10.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

¥ 36.84M

¥ 509
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Good growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Pharmarise Holdings Corporation predominantly oversees a chain of pharmacies that dispense prescription medications throughout Japan. These establishments fulfill prescriptions provided by medical facilities, offering vital pharmaceutical services to patients. Beyond its primary dispensing activities, the company also manages drugstores and convenience stores, and retails cosmetic products. Additionally, it provides services including the safekeeping and administration of patient medical records for healthcare institutions, operates medical complex centers, and offers temporary staffing assistance. As of May 31, 2021, the corporation maintained a network of 347 outlets. Pharmarise Holdings Corporation was founded in 1984 and its main office is located in Tokyo, Japan.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is overpriced on P/E, 'cheap' on EV/E

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

20.10.2026 22:32

DeepSeek has made available a tool that helps it reduce the cost of AI operations

20.10.2026 21:47

"A Roller-Coaster Ride for Stocks": What Wall Street Is Saying Ahead of SpaceX's Earnings Report

20.10.2026 20:36

Why Cathie Wood’s team expects Tesla stock to rise more than 1,000%

20.10.2026 20:11

"A Vicious Cycle": What Risks Does Rising Bond Yields Pose to the Stock Market?

20.10.2026 19:39

‘Weak link’: French sovereign risk premium approaches 15-year high

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026